 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
| 12345678910111213...6364» |
- || Trodelvy (sacituzumab govitecan-hziy) / Gilead
Clinical, Retrospective data, Review, Journal: Safety profile of sacituzumab govitecan in patients with breast cancer: A systematic review and meta-analysis. (Pubmed Central) - Dec 2, 2024
Concerning rates of neutropenia, nausea diarrhea, and anemia were reported. We highlight the need for protocols establishing prophylactic measures and strategies to mitigate SG-related toxicity.
- || Trodelvy (sacituzumab govitecan-hziy) / Gilead
Review, Journal: Trop2-Targeted Molecular Imaging in Solid Tumors: Current Advances and Future Outlook. (Pubmed Central) - Dec 2, 2024
Notably, the U.S. Food and Drug Administration (FDA) has approved sacituzumab govitecan (SG), a novel Trop2-targeted agent, for treating triple-negative breast cancer (TNBC) and refractory urothelial cancer, highlighting the significance of Trop2 in clinical oncology...We critically evaluate the current state by examining the relevant applications, diagnostic accuracy, therapeutic efficacy, and inherent limitations. Finally, we analyze the challenges impeding widespread clinical application and offer insights into strategies for advancing the field, thereby guiding future research endeavors.
- |||| Tarpeyo (budesonide) / Calliditas, Stada
New P4 trial, Real-world evidence, Real-world: NefXtend: Efficacy and Safety of Extended TARPEYO (clinicaltrials.gov) - Dec 2, 2024
P4, N=60, Not yet recruiting, Sponsor: Calliditas Therapeutics AB
- | Trodelvy (sacituzumab govitecan-hziy) / Gilead, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion date, Trial primary completion date, Metastases: CA209-63Y: Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients (clinicaltrials.gov) - Dec 2, 2024
P1/2, N=46, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Finally, we analyze the challenges impeding widespread clinical application and offer insights into strategies for advancing the field, thereby guiding future research endeavors. Trial completion date: Oct 2025 --> Apr 2027 | Trial primary completion date: Oct 2024 --> Apr 2026
- || Kadcyla (ado-trastuzumab emtansine) / Roche, Trodelvy (sacituzumab govitecan-hziy) / Gilead, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Review, Journal: A Review of Current and Future Antibody Drug Conjugates in Breast Cancer. (Pubmed Central) - Nov 29, 2024
The future of this class of compounds is very exciting. This field is rapidly evolving with new ADCs being investigated and clinical trials looking at the use of known ADCs in earlier stage disease.
- | Xerava (eravacycline) / SOM Biotech, Ewha Womans University, PAION, Innoviva
Journal: Outcomes of adjunctive eravacycline for severe and fulminant Clostridioides difficile infection. (Pubmed Central) - Nov 28, 2024
Patients receiving ERV often were immunocompromised and had fulminant disease with critical illness. Future comparative studies are needed to evaluate the impact of adjunctive ERV for CDI.
- || Xerava (eravacycline) / SOM Biotech, Ewha Womans University, PAION, Innoviva
Retrospective data, Review, Journal, Gram negative: Efficacy and safety of eravacycline (ERV) in treating infections caused by Gram-negative pathogens: a systematic review and meta-analysis. (Pubmed Central) - Nov 28, 2024
Patients in RCTs received ERV monotherapy, whereas almost half of the patients in cohort studies were treated with ERV in combination with other antibiotics. Further studies are warranted to investigate the safety and efficacy of ERV monotherapy or combination therapy in critically ill patients.
- | Journal: Novel Antibiotics for Urinary Tract Infection (UTI): The EAGLE 2 and EAGLE-3 Trials for Uncomplicated UTI, and the CERTAIN-1 Trial for Complicated UTI. (Pubmed Central) - Nov 27, 2024
Gepotidacin was an efficacious first-in-class oral antibiotic in uncomplicated UTI in comparison to nitrofurantoin. Cefepime/taniborbactam was superior to meropenem in complicated UTI and acute pyelonephritis.
- | imipenem/relebactam / Merck (MSD), Vabomere (meropenem/vaborbactam) / Melinta Therap, Menarini, Xerava (eravacycline) / SOM Biotech, Ewha Womans University, PAION, Innoviva
Journal, Gram negative: Colistin, Meropenem-Vaborbactam, Imipenem-Relebactam, and Eravacycline Testing in Carbapenem-Resistant Gram-Negative Rods: A Comparative Evaluation of Broth Microdilution, Gradient Test, and VITEK 2. (Pubmed Central) - Nov 27, 2024
VITEK 2 was mostly accurate in measuring ERV MICs, while the corresponding gradient test yielded reliable results exclusively in CREs. It is essential that laboratories are aware of which testing method provides reliable results for each combination of microorganisms and reserve antibiotics.
- | Velsipity (etrasimod) / Pfizer
Journal: Low Incidence of Macular Edema and Other Ocular Events in the Etrasimod Development Program. (Pubmed Central) - Nov 22, 2024
Macular edema and other ocular events were uncommon in patients treated with etrasimod across multiple conditions. Incidence of Macular edema was comparable with placebo.
- || Retrospective data, Review, Journal, Metastases: Antibody-drug conjugates in patients with advanced/metastatic HER2-low-expressing breast cancer: a systematic review and meta-analysis. (Pubmed Central) - Nov 22, 2024
Future studies should focus on bringing ADCs into earlier lines of therapy in this population. This study was registered in PROSPERO (CRD42024452962).
- || Kadcyla (ado-trastuzumab emtansine) / Roche, Trodelvy (sacituzumab govitecan-hziy) / Gilead, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Clinical data, Review, Journal: Unveiling the future of breast cancer therapy: Cutting-edge antibody-drug conjugate strategies and clinical outcomes. (Pubmed Central) - Nov 21, 2024
This review summarizes the efficacy and adverse effects of ADC therapies that have completed or are currently undergoing phase I-III clinical trials. Additionally, it analyzes potential combination strategies to overcome ADC resistance, aiming to provide clinicians with a comprehensive clinical guide to the use of ADCs in breast cancer treatment.
- || Trodelvy (sacituzumab govitecan-hziy) / Gilead, Opdivo (nivolumab) / BMS
Enrollment open: Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence (clinicaltrials.gov) - Nov 21, 2024
P2, N=23, Recruiting, Sponsor: University of California, Irvine
Additionally, it analyzes potential combination strategies to overcome ADC resistance, aiming to provide clinicians with a comprehensive clinical guide to the use of ADCs in breast cancer treatment. Not yet recruiting --> Recruiting
- Trodelvy (sacituzumab govitecan-hziy) / Gilead
TROPiCS-04, a randomized phase III study of sacituzumab govitecan (SG) vs chemotherapy (CT) in pretreated advanced urothelial carcinoma (aUC): Overall survival (OS) and safety analysis (Hall 406) - Nov 20, 2024 - Abstract #ESMOAsia2024ESMO_Asia_1382;
- ||| Trodelvy (sacituzumab govitecan-hziy) / Gilead
Journal, Adverse events: Mining and influencing factors analysis of sacituzumab govitecan adverse drug event based on FAERS database. (Pubmed Central) - Nov 19, 2024
Common ADEs and the involved organ systems generally correspond with the prescribing information. Clinicians should be vigilant regarding unlisted ADEs when using sacituzumab govitecan, and close monitoring of laboratory indicators ensure patient medication safety.
- | zetomipzomib (KZR-616) / Kezar
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: A Study of Zetomipzomib (KZR-616) in Patients with Active Lupus Nephritis (PALIZADE) (clinicaltrials.gov) - Nov 19, 2024
P2, N=84, Terminated, Sponsor: Kezar Life Sciences, Inc.
Clinicians should be vigilant regarding unlisted ADEs when using sacituzumab govitecan, and close monitoring of laboratory indicators ensure patient medication safety. N=279 --> 84 | Trial completion date: Jul 2026 --> Nov 2024 | Suspended --> Terminated | Trial primary completion date: May 2026 --> Nov 2024; Sponsor Decision.
- | Trodelvy (sacituzumab govitecan-hziy) / Gilead
Journal: Long-term efficacy and safety with sacituzumab govitecan in a patient with triple-negative breast cancer, multi-treated and high body mass index. (Pubmed Central) - Nov 18, 2024
The presented clinical case documents the efficacy and safety of long-term treatment with SG in an obese young woman with mTNBC who has already undergone multiple treatments. The patient is still responding after 20 months of treatment with good quality of life and social interactions.
- | Trodelvy (sacituzumab govitecan-hziy) / Gilead
Journal, BRCA Biomarker: Use of sacituzumab govitecan in frail patients with skin disease. (Pubmed Central) - Nov 18, 2024
The patient has no family history of breast cancer and does not have a mutation in the BRCA1/2 genes. In pathological history, only arterial hypertension under medical therapy with nebivolol.
- | Trodelvy (sacituzumab govitecan-hziy) / Gilead
Journal, Metastases: Sacituzumab govitecan nel trattamento delle pazienti pluritrattate affette da tumore della mammella triplo negativo metastatico. (Pubmed Central) - Nov 18, 2024
In pathological history, only arterial hypertension under medical therapy with nebivolol. No abstract available
- | Trodelvy (sacituzumab govitecan-hziy) / Gilead
Journal: Sacituzumab govitecan in a triple-negative breast cancer patient journey: a cutting-edge story. (Pubmed Central) - Nov 18, 2024
Thanks to SG use within a multimodal patient journey, a sustained disease control along with a preserved quality of life was gained. Further real-world data is awaited to confirm these findings.
- | Trodelvy (sacituzumab govitecan-hziy) / Gilead
Journal: Activity of sacituzumab govitecan in skin metastases: description of a case. (Pubmed Central) - Nov 18, 2024
However, recent developments in molecular research and targeted therapy are opening up new perspectives with encouraging results for the treatment of this aggressive disease. The shared case wants to be an example: we will discuss the story of a 54 years old woman with extensive metastatic localizations in the skin that has obtained an important clinical response to therapy with sacituzumab govitecan, a conjugate antibody approved for the treatment of adult patients with metastatic triple negative breast cancer.
- | Trodelvy (sacituzumab govitecan-hziy) / Gilead
Journal: Sacituzumab govitecan in the second line treatment in a patient with triple-negative breast cancer with extensive locoregional recurrence. (Pubmed Central) - Nov 18, 2024
She continued treatment for a total of 9 cycles. The case confirms the clinical benefit and effectiveness of treatment with SG, in particular it underlines the good control of the disease characterized by a rapid and progressive course with exclusively locoregional extension and good control of symptoms with an improvement in quality of life.
- | Trodelvy (sacituzumab govitecan-hziy) / Gilead
Journal, Metastases: Sacituzumab govitecan nel trattamento di popolazioni speciali di pazienti con tumore mammario metastatico triplo negativo. (Pubmed Central) - Nov 18, 2024
The case confirms the clinical benefit and effectiveness of treatment with SG, in particular it underlines the good control of the disease characterized by a rapid and progressive course with exclusively locoregional extension and good control of symptoms with an improvement in quality of life. No abstract available
- | Trodelvy (sacituzumab govitecan-hziy) / Gilead
Journal: Dual immunostimulatory CD73 antibody-polymeric cytotoxic drug complex for triple negative breast cancer therapy. (Pubmed Central) - Nov 17, 2024
However, the current ADC, sacituzumab govitecan, fails to overcome the crucial role of adenosine in the suppressive immune microenvironment characteristic of this "cold tumor"...Thus, it kills tumor cells with cytotoxic drugs, comprehensively regulates immunosuppression, and restores a durable immune response. This study proposes an antibody-polymeric drug complex with immunomodulatory and immunoagonist roles, offering new insights into TNBC treatment.
- | Trodelvy (sacituzumab govitecan-hziy) / Gilead
Journal, Metastases: Exposure-Response Analyses of Sacituzumab Govitecan Efficacy and Safety in Patients With Metastatic Triple-Negative Breast Cancer. (Pubmed Central) - Nov 17, 2024
Neutropenia was the only evaluated AE for which CAVGSG was significantly associated with grade ?3 events. The clinically meaningful efficacy and manageable safety achieved with SG 10?mg/kg on days 1 and 8 of every 21-day cycle dosing regimen supports the appropriateness of this clinical dosage in patients with mTNBC.
- || Zeposia (ozanimod) / BMS
Review, Journal: The discovery and development of the sphingosine 1-phosphate receptor modulator ozanimod in ulcerative colitis. (Pubmed Central) - Nov 16, 2024
In this review, the discovery and development of the first approved S1P modulator, ozanimod, is described in detail: from design of initial screens to discover unique binding agents, to extensive chemical modifications to improve pharmacokinetic and safety profiles, and through preclinical and clinical studies validating mechanism and establishing safety and efficacy. Ultimately, this review will not only inform the reader of the unique path to development of a clinical S1P modulator for UC, but will also highlight advances made and gaps remaining to individualize therapeutic approaches for inflammatory bowel disease.
- | Xerava (eravacycline) / SOM Biotech, Ewha Womans University, PAION, Innoviva
Journal: Eradication of Pseudomonas aeruginosa Persister Cells by Eravacycline. (Pubmed Central) - Nov 16, 2024
The effects of eravacycline on persister control were further validated in vivo using a lung infection model in mice. Collectively, these results demonstrate the possibility to control persister cells of bacterial pathogens by targeting dormancy.
- | Xerava (eravacycline) / SOM Biotech, Ewha Womans University, PAION, Innoviva
Journal, Combination therapy: Combination Therapy of Trimethoprim-Sulfamethoxazole (TMP-SMZ) and Eravacycline for Treating Elizabethkingia anophelis-Induced Pulmonary Infections: A Case Report. (Pubmed Central) - Nov 15, 2024
Additionally, this report provides a summary of high-risk factors for E. anophelis infection, clinical manifestations, and therapeutic options. Given the high degree of antimicrobial drug resistance of the organism and the fact that inappropriate empirical antimicrobial therapy constitutes a risk factor for mortality, our case serves as a valuable reference for similar cases, highlighting potential strategies for effective management.
- || Trodelvy (sacituzumab govitecan-hziy) / Gilead
Clinical, Review, Journal: Sacituzumab Govitecan in Triple Negative Breast Cancer: A Systematic Review of Clinical Trials. (Pubmed Central) - Nov 15, 2024
The efficacy results showed a significantly greater clinical benefit with sacituzumab govitecan compared to standard chemotherapy in patients with triple-negative breast cancer. This drug will become a treatment of substantial impact in future treatment guidelines for this type of cancer.
- ||| Velsipity (etrasimod) / Pfizer
P2 data, P3 data, Journal, Adverse events, Serious adverse event: Non-serious adverse events in patients with ulcerative colitis receiving etrasimod: an analysis of the phase II OASIS and phase III ELEVATE UC 52 and ELEVATE UC 12 clinical trials. (Pubmed Central) - Nov 15, 2024
P2, P3
These results reiterate the favourable safety profile and tolerability of etrasimod. ClinicalTrials.gov: NCT02447302; NCT03945188; NCT03996369.
- | Yutuo (zimberelimab) / Arcus Biosci, Gilead
Trial completion date, Trial primary completion date: ARIAN: Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free. (clinicaltrials.gov) - Nov 14, 2024
P2, N=129, Not yet recruiting, Sponsor: Fundaci
ClinicalTrials.gov: NCT02447302; NCT03945188; NCT03996369. Trial completion date: Jun 2031 --> Nov 2031 | Trial primary completion date: Jun 2031 --> Nov 2031
- ||| Trodelvy (sacituzumab govitecan-hziy) / Gilead
Trial completion, Enrollment change: Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy (clinicaltrials.gov) - Nov 14, 2024
P4, N=25, Completed, Sponsor: Gilead Sciences
Trial completion date: Jun 2031 --> Nov 2031 | Trial primary completion date: Jun 2031 --> Nov 2031 Enrolling by invitation --> Completed | N=200 --> 25
- | bleomycin / Generic mfg., roblitinib (FGF401) / Everest Medicines
Journal: Identification of FGFR4 as a regulator of myofibroblast differentiation in Pulmonary Fibrosis. (Pubmed Central) - Nov 13, 2024
signaling in vitro. However, the inhibition of FGFR4 is not sufficient to prevent the development of pulmonary fibrosis in vivo.
- | Xerava (eravacycline) / SOM Biotech, Ewha Womans University, PAION, Innoviva
Journal, PD(L)-1 Biomarker, IO biomarker: Eravacycline improves the efficacy of anti-PD1 immunotherapy via AP1/CCL5 mediated M1 macrophage polarization in melanoma. (Pubmed Central) - Nov 13, 2024
As expected, application of ERV improved the efficacy of anti-PD1. Overall, our results approved that ERV enhances the efficacy of anti-PD1 immunotherapy in melanoma by promoting the polarization of M1 macrophages, which provided novel therapeutic strategy for improving the effectiveness of melanoma anti-PD1 immunotherapy.
- | Trodelvy (sacituzumab govitecan-hziy) / Gilead
Journal, IO biomarker: Genomic, immunologic, and prognostic associations of TROP2 (TACSTD2) expression in solid tumors. (Pubmed Central) - Nov 13, 2024
Overall, our results approved that ERV enhances the efficacy of anti-PD1 immunotherapy in melanoma by promoting the polarization of M1 macrophages, which provided novel therapeutic strategy for improving the effectiveness of melanoma anti-PD1 immunotherapy. TACSTD2 expression is associated with key driver alterations and a more active immune microenvironment, suggesting possible combinatorial strategies with TROP2-targeting ADCs plus immunotherapy in various solid tumors.
- | Journal, PD(L)-1 Biomarker, IO biomarker, Metastases: Targeted and immunotherapy for the management of advanced urothelial carcinoma of the bladder. (Pubmed Central) - Nov 13, 2024
Pembrolizumab, with and without enfortumab, has demonstrated first-line activity, and avelumab is a key maintenance therapy after first-line treatment. The results of additional clinical trials should provide evidence to establish the exact role in therapy of each agent in patients with advanced disease.
- |||| Trodelvy (sacituzumab govitecan-hziy) / Gilead, Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open: NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III) (clinicaltrials.gov) - Nov 12, 2024
P2, N=348, Recruiting, Sponsor: West German Study Group
The results of additional clinical trials should provide evidence to establish the exact role in therapy of each agent in patients with advanced disease. Not yet recruiting --> Recruiting
- || Trodelvy (sacituzumab govitecan-hziy) / Gilead, Opdivo (nivolumab) / BMS
New P2 trial: Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence (clinicaltrials.gov) - Nov 12, 2024
P2, N=23, Not yet recruiting, Sponsor: University of California, Irvine
- | Tarpeyo (budesonide) / Calliditas, Stada
Trial completion, Enrollment change, Trial completion date: Efficacy and Safety in Chinese Patients with Immunoglobulin a Nephropathy (IgAN) Who Have Completed Study Nef-301 (clinicaltrials.gov) - Nov 12, 2024
P3, N=21, Completed, Sponsor: Everest Medicines (Singapore) Pte. Ltd.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | N=58 --> 21 | Trial completion date: Dec 2024 --> Jul 2024
- || Trodelvy (sacituzumab govitecan-hziy) / Gilead
Enrollment closed, Metastases: Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric Adenocarcinoma (clinicaltrials.gov) - Nov 12, 2024
P1/2, N=56, Active, not recruiting, Sponsor: Institut f
Active, not recruiting --> Completed | N=58 --> 21 | Trial completion date: Dec 2024 --> Jul 2024 Recruiting --> Active, not recruiting
- | Xerava (eravacycline) / SOM Biotech, Ewha Womans University, PAION, Innoviva
New trial: The efficacy and safety observation study of Eravacycline treatment in patients with neutropenia and fever: A multicenter retrospective cohort study based on HIS data (EUDRACT) - Nov 10, 2024
P=N/A, N=200, Not yet recruiting, Sponsor: Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Institute of Hematology and
- | cefepime/taniborbactam (cefepime/VNRX-5133) / VenatoRx
Preclinical, Journal: Cefepime-taniborbactam demonstrates potent in vitro activity vs Enterobacterales with blaOXA-48. (Pubmed Central) - Nov 7, 2024
CLSI-based agar dilution susceptibility testing was conducted using FEP-taniborbactam and comparators FEP, meropenem-vaborbactam (MVB), and ceftazidime-avibactam (CZA). Notably, cefepime-taniborbactam MIC50/MIC90 values (0.5/4
- Trodelvy (sacituzumab govitecan-hziy) / Gilead
A phase II study of Sacituzumab Govitecan in recurrent glioblastoma (Hall B3) - Nov 7, 2024 - Abstract #SNO2024SNO_710;
- || Emblaveo (aztreonam/avibactam) / Pfizer, AbbVie, Xerava (eravacycline) / SOM Biotech, Ewha Womans University, PAION, Innoviva
Clinical, Preclinical, Journal: In vitro activities of the essential antimicrobial agents including aztreonam/avibactam, eravacycline, colistin, and other comparators against carbapenem-resistant bacteria with different carbapenemase genes: a multicenter study in China, 2021. (Pubmed Central) - Nov 6, 2024
Using aztreonam/avibactam, eravacycline and colistin to treat infections caused by CRB offers significant advantages. These findings will guide clinical practice and optimize antimicrobial administration.
- | Journal: Assessment of the activity and mechanisms of resistance to cefiderocol and combinations of ?-lactams and the novel ?-lactamase inhibitors avibactam, taniborbactam, zidebactam, nacubactam, xeruborbactam, and ANT3310 in emerging double-carbapenemase-producing Enterobacterales. (Pubmed Central) - Nov 6, 2024
Meropenem/ANT3310 (MIC50/MIC90 = 0.5/?64 mg/L; 47/57 susceptible) and cefepime/taniborbactam (MIC50/MIC90 = 0.5/16 mg/L; 44/57 susceptible) also retained high levels of activity, although they were affected by NDM-type enzymes in combination with porin deficiency. Our findings highlight that cefiderocol and combinations of ?-lactams and the novel ?-lactamase inhibitors avibactam, nacubactam, taniborbactam, zidebactam, xeruborbactam, and ANT3310 show promising activity against double-carbapenemase-producing Enterobacterales.
- Trodelvy (sacituzumab govitecan-hziy) / Gilead, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Analysis of the Clinical Impact of the Time to Reimbursement of New Oncology Drugs in Spain: A Case Study in Breast Cancer () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_2342;
Two molecules were analysed: trastuzumab-deruxtecan in unresectable/metastatic HER2+ and HER2-low breast cancer (BC); and sacituzumab-govitecan in unresectable/metastatic triple-negative BC (mTNBC). These results provide possible metrics to quantify the benefits that can be obtained if time to availability of medicines for patients is cut short through planned public policies.
- Trodelvy (sacituzumab govitecan-hziy) / Gilead, Talzenna (talazoparib) / Pfizer, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Comparative Analysis of HTA Decisions for Metastatic Breast Cancer Treatments in Nordic Countries () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_2129;
These results provide possible metrics to quantify the benefits that can be obtained if time to availability of medicines for patients is cut short through planned public policies. Denmark exhibited more restrictive recommendations, with certain treatments like Trodelvy
- Trodelvy (sacituzumab govitecan-hziy) / Gilead, datopotamab deruxtecan (DS-1062a) / Daiichi Sankyo, AstraZeneca
The Economic Burden of Managing Grade ?3 AEs Following Treatment of Inoperable/Metastatic HR-Positive/HER2-Negative Breast Cancer in Italy, Spain and the United States () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1194;
Dato-DXd has an acceptable safety profile in HR+/HER2- BC and is associated with lower costs of managing G3AEs in Italy, Spain and the US compared with SG and ICC. The results should be interpreted with caution due to cross trial and country differences in AE management.
- Trodelvy (sacituzumab govitecan-hziy) / Gilead
Comparative Clinical Effectiveness of Medicinal Products: Evaluation of International Criteria and Application to the NCPE HTA Process () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_73;
The rationale for how these criteria inform comparative clinical effectiveness ratings is often unclear, leading to heterogeneous conclusions across the methods. Further research will involve the application of these appraisal methods to other NCPE HTA appraisals.
- Trodelvy (sacituzumab govitecan-hziy) / Gilead
Bridging Gaps in TNBC: Comparative Analysis of Patient Demographics and Treatment Patterns Between Australia and EU4+UK Countries (Halls 1 & 2) - Nov 3, 2024 - Abstract #COSA2024COSA_318;
This study highlights disparities in treatment funding, particularly in the UK and therapy utilisation between Australia and EU4+UK countries, underscoring the need for aligned treatment protocols and equitable access to care. Bridging these gaps will facilitate progress in global cancer care, breaking down disparities and potentially improving outcomes for TNBC patients worldwide.